Asset profile
ION904
RNA / oligonucleotide
Evidence outlook · program status
Discontinued (2024), for reasons the sponsor has not stated
ION904 was Ionis's next-generation LICA antisense medicine targeting angiotensinogen for uncontrolled hypertension. The FY2023 Form 10-K reported positive Phase 2 data 'supportive of continued development', but ION904 and the word angiotensinogen appear nowhere in this FY2025 Form 10-K, which enumerates the marketed medicines and the late- and mid-stage pipeline in full; EDGAR full-text search finds ION904 in no Ionis annual report after the one filed 2024-02-21. Ionis is alive and gives no reason, so the reason is unknown and the stop is dated to the first annual report that omits it. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 4 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 36 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| ION904: this drug | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | ||
| Zilebesiran | Phase 3 | RNA / oligonucleotide | Angiotensinogen (AGT) | ||
| IBI3016 | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | ||
| Tonlamarsen | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | ||
| ADX-850 | Phase 1 | RNA / oligonucleotide | Angiotensinogen (AGT) | ||
| Aprocitentan (Tryvio) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Bosentan (Tracleer) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Epoprostenol (Flolan) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| Nitric Oxide (INOmax) | Approved | Gas (inhaled) | Nitric oxide | ||
| Sacubitril / Valsartan (Entresto) | Approved | Small molecule | Neprilysin + Angiotensin II receptor (dual) | ||
| Treprostinil (Orenitram / Remodulin / Tyvaso) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| Treprostinil (Yutrepia, Liquidia) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| AD-209 | Phase 3 | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel / Na-Cl cotransporter | ||
| AGSAVI | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | ||
| AJU-C52 | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.